FOXN3 下调在急性髓系白血病中的临床和预后意义。
The clinical and prognostic significance of FOXN3 downregulation in acute myeloid leukaemia.
机构信息
Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.
出版信息
Int J Lab Hematol. 2020 Jun;42(3):270-276. doi: 10.1111/ijlh.13162. Epub 2020 Feb 20.
INTRODUCTION
The expression of forkhead box N3 (FOXN3), also known as checkpoint suppressor 1 (CHES1), is reduced in many types of tumours. However, the clinical significance of FOXN3 and its potential role in acute myeloid leukaemia (AML) remain largely unknown.
METHODS
A total of 117 de novo AML patients newly diagnosed between December 2015 and January 2018 were included in this study. The expression of FOXN3 and its clinical significance were analysed in these AML patients.
RESULTS
The expression of FOXN3 was significantly downregulated in AML. In addition, lower FOXN3 expression was associated with older age and higher white blood cell counts. Moreover, a close correlation was observed between lower FOXN3 expression and a lower complete remission (CR) rate and shorter overall survival (OS), which was further analysed by multivariate analysis.
CONCLUSION
These data suggest that FOXN3 is a novel biomarker in AML and that lower FOXN3 expression predicts poor chemotherapy response and prognosis in AML.
简介
叉头框 N3（FOXN3）的表达，也称为检查点抑制剂 1（CHES1），在许多类型的肿瘤中减少。然而，FOXN3 的临床意义及其在急性髓系白血病（AML）中的潜在作用在很大程度上仍然未知。
方法
本研究共纳入 117 例 2015 年 12 月至 2018 年 1 月新诊断的初治 AML 患者。分析这些 AML 患者中 FOXN3 的表达及其临床意义。
结果
FOXN3 在 AML 中表达明显下调。此外，FOXN3 表达水平较低与年龄较大和白细胞计数较高有关。此外，通过多变量分析进一步分析发现，FOXN3 表达水平较低与较低的完全缓解（CR）率和较短的总生存期（OS）密切相关。
结论
这些数据表明，FOXN3 是 AML 的一个新的生物标志物，FOXN3 表达水平较低预示着 AML 化疗反应不良和预后不良。
Zotero 插件